Johnson & Johnson (NYSE:JNJ) Shares Up 1.5% – What’s Next?
by Mitch Edgeman · The Markets DailyShares of Johnson & Johnson (NYSE:JNJ – Get Free Report) traded up 1.5% on Thursday . The stock traded as high as $260.20 and last traded at $259.3410. 7,872,627 shares traded hands during mid-day trading, a decline of 7% from the average daily volume of 8,453,166 shares. The stock had previously closed at $255.63.
Johnson & Johnson News Summary
Here are the key news stories impacting Johnson & Johnson this week:
- Positive Sentiment: Johnson & Johnson reported positive Phase 3 results for its multiple myeloma regimen TECVAYLI + TALVEY, showing a significant reduction in disease progression and death risk versus standard of care. The data reinforce J&J’s leadership in hematology oncology and could support future growth in its pharma portfolio. Article Title
- Positive Sentiment: The FDA granted De Novo authorization for J&J’s OTTAVA robotic surgical system, giving the company a new entry point into the soft-tissue surgical robotics market and creating a potential long-term growth driver for MedTech. Article Title
- Positive Sentiment: A federal judge cast doubt on roughly 69,000 talc-related cancer claims against J&J, saying plaintiffs need more specific evidence or risk dismissal. That could ease some legal overhang tied to the company’s long-running litigation. Article Title
- Neutral Sentiment: Commentary around J&J’s strong Q2 earnings beat and bullish 2026 outlook is drawing more attention from healthcare ETFs and investors, but this is largely a follow-on reaction rather than new company-specific news. Article Title
Analyst Ratings Changes
JNJ has been the subject of several analyst reports. HSBC set a $290.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Monday, July 6th. Argus increased their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research note on Thursday, April 16th. Daiwa Securities Group lifted their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a report on Thursday, April 16th. Weiss Ratings downgraded shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, June 15th. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $265.30.
View Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Stock Performance
The stock has a 50-day moving average of $241.40 and a 200 day moving average of $235.76. The firm has a market capitalization of $624.29 billion, a P/E ratio of 30.05, a price-to-earnings-growth ratio of 2.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.68 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.
Insider Buying and Selling
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Johnson & Johnson
Large investors have recently modified their holdings of the stock. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth approximately $954,000. World Investment Advisors increased its stake in Johnson & Johnson by 19.6% in the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after acquiring an additional 26,450 shares during the last quarter. Benchmark Financial LLC acquired a new position in Johnson & Johnson during the fourth quarter valued at approximately $554,000. Robinhood Asset Management LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $11,853,000. Finally, Principal Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 0.8% in the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock valued at $705,736,000 after purchasing an additional 28,370 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.